PriceTargets.com logo

Ginkgo Bioworks - DNA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.10
  • Forecasted Upside: 163.67%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.56 As of 06/2/2023 11:34 AM ET
▼ -0.125 (-7.44%)

This chart shows the closing price for DNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ginkgo Bioworks Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DNA

Analyst Price Target is $4.10
▲ +163.67% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Ginkgo Bioworks in the last 3 months. The average price target is $4.10, with a high forecast of $6.00 and a low forecast of $1.25. The average price target represents a 163.67% upside from the last price of $1.56.

This chart shows the closing price for DNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Ginkgo Bioworks. This rating has held steady since February 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/8/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/2/2023The Goldman Sachs GroupDowngradeNeutral ➝ Sell$3.00 ➝ $1.25Low
5/11/2023William BlairDowngradeOutperform ➝ Market PerformLow
3/5/2023BTIG ResearchLower Target$4.00 ➝ $3.00Low
3/3/2023Raymond JamesLower TargetOutperform$6.00 ➝ $5.00Low
11/28/2022Berenberg BankInitiated CoverageBuy$6.00Low
11/22/2022Raymond JamesLower TargetOutperform$10.50 ➝ $6.00Low
11/17/2022BTIG ResearchLower Target$4.00Low
11/16/2022Raymond JamesLower TargetOutperform$14.50 ➝ $10.50Low
10/4/2022Morgan StanleyInitiated CoverageEqual Weight$5.00Low
8/16/2022BTIG ResearchBoost TargetBuy$5.00 ➝ $6.00Low
8/16/2022Raymond JamesBoost TargetOutperform$11.50 ➝ $14.50Low
6/16/2022Jefferies Financial GroupLower Target$11.50 ➝ $4.35High
5/18/2022BTIG ResearchLower TargetNA$5.00Medium
5/18/2022Bank of AmericaDowngradeNeutral ➝ Underperform$3.00High
5/17/2022Raymond JamesSet TargetOutperform$11.50Low
4/25/2022Raymond JamesSet TargetOutperform$11.50High
4/5/2022Raymond JamesLower TargetOutperform$14.50 ➝ $11.50Low
3/31/2022BTIG ResearchLower Target$12.00 ➝ $6.00High
3/29/2022Raymond JamesSet TargetOutperform$14.50Low
3/2/2022CowenInitiated CoverageOutperform$12.00Medium
2/23/2022The Goldman Sachs GroupInitiated CoverageNeutral$7.00High
2/1/2022Bank of AmericaReiterated RatingNeutral$6.00High
1/28/2022Bank of AmericaInitiated CoverageBuy$8.00High
1/14/2022Raymond JamesReiterated RatingOutperform$18.00Medium
1/7/2022BTIG ResearchInitiated CoverageBuy$12.00High
11/29/2021Jefferies Financial GroupInitiated CoverageBuyMedium
11/12/2021Raymond JamesSet TargetOutperform$14.50Low
10/29/2021Raymond JamesSet TargetOutperform$14.50Low
10/19/2021Raymond JamesSet TargetOutperform$14.50High
10/13/2021Raymond JamesInitiated CoverageOutperform$14.50Low
10/12/2021William BlairInitiated CoverageOutperformHigh
9/20/2021HSBCInitiated CoverageBuy$14.00N/A
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2022
  • 6 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2023
  • 9 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2023
  • 9 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/4/2023
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 8 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 11 very positive mentions
  • 33 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 11 very positive mentions
  • 33 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Ginkgo Bioworks logo
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.56
Low: $1.51
High: $1.69

50 Day Range

MA: $1.33
Low: $1.14
High: $1.73

52 Week Range

Now: $1.56
Low: $1.12
High: $4.91

Volume

13,216,983 shs

Average Volume

20,072,236 shs

Market Capitalization

$3.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Ginkgo Bioworks?

The following Wall Street research analysts have issued stock ratings on Ginkgo Bioworks in the last year: Berenberg Bank, BTIG Research, Jefferies Financial Group Inc., Morgan Stanley, Raymond James, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for DNA.

What is the current price target for Ginkgo Bioworks?

6 Wall Street analysts have set twelve-month price targets for Ginkgo Bioworks in the last year. Their average twelve-month price target is $4.10, suggesting a possible upside of 166.2%. Berenberg Bank has the highest price target set, predicting DNA will reach $6.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $1.25 for Ginkgo Bioworks in the next year.
View the latest price targets for DNA.

What is the current consensus analyst rating for Ginkgo Bioworks?

Ginkgo Bioworks currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DNA, but not buy more shares or sell existing shares.
View the latest ratings for DNA.

What other companies compete with Ginkgo Bioworks?

Other companies that are similar to Ginkgo Bioworks include Abcam, Vir Biotechnology, Denali Therapeutics, Krystal Biotech and Halozyme Therapeutics. Learn More about companies similar to Ginkgo Bioworks.

How do I contact Ginkgo Bioworks' investor relations team?

Ginkgo Bioworks' physical mailing address is 955 Fifth Avenue, New York NY, 10075. The company's listed phone number is 877-442-5362 and its investor relations email address is [email protected]. The official website for Ginkgo Bioworks is www.eagleequityptnrs.com. Learn More about contacing Ginkgo Bioworks investor relations.